Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY:PFE)

22.60 +0.58 (+2.63%)
Official Closing Price Updated: 7:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints. 
Via Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
Check Out What Whales Are Doing With PFE
Via Benzinga
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Neither is a leader right now, but one of them might be on track to change that. 
Via The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
The pharma's latest push to develop a weight loss pill isn't going well. 
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept. 
Via Benzinga
Exposures COVID-19
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... 
Via Benzinga
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE: PFE) is showing a bullish Golden Cross, indicating potential upward momentum for the stock. 
Via Benzinga
Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said he is staying long on Pfizer Inc. 
Via Benzinga
7 Hated Stocks Set to Make a Major Comeback This Year
These seven out-of-favor stocks across various sectors have the potential to stage a significant rebound as market conditions improve. 
Via InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. 
Via InvestorPlace
Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
Despite their recent underperformance, these two phenomenal dividend stocks -- sporting an average yield of 5.79% -- have the recipes to make their patient shareholders notably richer. 
Via The Motley Fool
Current Analysis: Pfizer Inc.
Pfizer (PFE​​​​​​​) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer’s share price rose about 20.5% from $36.32 to $30.02 as of... 
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On... 
Via Benzinga
3 Under $50 Stocks to Buy Now: Q3 Edition
For small do-it-yourself investors looking for value, the following under $50 stocks are worth buying in July 2024. 
Via InvestorPlace
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years. 
Via The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
2 Pharma Stocks to Buy Hand Over Fist This Month
These drugmakers may not be in perfect health right now, but that shouldn't last much longer. 
Via The Motley Fool
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector underperforms. 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.